Da human IgG udskilles i human mælk, og potentialet for skade på spædbarnet er ukendt, bør kvinder ikke amme, mens de bliver behandlet med Osigraft.
As human IgG is secreted into human milk, and the potential for harm to the infant is unknown, women should not breast-feed during Osigraft therapy.